M&A Trend Picks Up Steam
The beat goes on as Amgen agrees to buy Micromet (MITI $10.95) for $1.16B.Micromet is focused on treatment of hematologic malignancies with its BiTE monoclonal antibody platform and has four clinical stage product candidates. The stock was $5 on November 25 ,2011.
Micromet was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $4.
This is beginning to feel like the biotech market of 1999.